CLINUVEL announced the launch of the first of four healthcare product lines with CYACÊLLE, a polychromatic screen, or next generation of solar care (3), formulated to protect skin against ultraviolet B (UVB), ultraviolet A (UVA), and high-energy visible (HEV) light. The Company successfully developed the systemic photoprotective pharmaceutical, SCENESSE ® (afamelanotide 16mg), treating patients intolerant to light due to the genetic disease erythropoietic protoporphyria (EPP). Consequently, CLINUVEL has been in the best position to translate its technological and clinical knowhow to non-prescription products for people at highest risk of light-induced skin damage.

The objectives of the Company are to solve medical and healthcare problems for those who have remained unattended and unaddressed (unmet need). The Group distinguishes itself by long-term follow up of its partners, suppliers, patients, and physicians, and now aims to continue a longitudinal approach to specialised populations. As the first of four product lines, CYACÊLLE provides localised skin protection benefiting three distinct populations at highest risk of photodamage and skin cancer(s).

These are individuals who are longer-term immune-suppressed (IS), affected by skin cancers (SC) either personally or within their immediate family, and those who spend extended time outdoors (EO), such as farmers, outdoor and construction workers, and professional athletes.